In this study, cancers with high GLUT1 expression had higher rates of ER negativity, PR negativity, HER2 positivity, Ki67 positivity, high-grade, and HER2-overexpressing and triple-negative subtypes. The gene discussed is SLC2A1; the disease is cancer.